TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis
USA - NYSE:TDOC - US87918A1051 - Common Stock
7.57 USD
+0.04 (+0.53%)
We assign a fundamental rating of 3 out of 10 to TDOC. TDOC was compared to 35 industry peers in the Health Care Technology industry. TDOC has a bad profitability rating. Also its financial health evaluation is rather negative. TDOC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
TDOC had negative earnings in the past year.
TDOC had a positive operating cash flow in the past year.
TDOC had negative earnings in each of the past 5 years.
Of the past 5 years TDOC 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -7.77%, TDOC is in the better half of the industry, outperforming 62.86% of the companies in the same industry.
The Return On Equity of TDOC (-16.06%) is better than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -16.06% | ||
| ROIC | N/A |
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TDOC's Gross Margin of 69.80% is fine compared to the rest of the industry. TDOC outperforms 74.29% of its industry peers.
TDOC's Gross Margin has been stable in the last couple of years.
TDOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TDOC has more shares outstanding
The number of shares outstanding for TDOC has been increased compared to 5 years ago.
Compared to 1 year ago, TDOC has a worse debt to assets ratio.
2.2 Solvency
TDOC has an Altman-Z score of -6.48. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
TDOC has a worse Altman-Z score (-6.48) than 82.86% of its industry peers.
The Debt to FCF ratio of TDOC is 7.09, which is on the high side as it means it would take TDOC, 7.09 years of fcf income to pay off all of its debts.
TDOC has a Debt to FCF ratio (7.09) which is in line with its industry peers.
A Debt/Equity ratio of 0.71 indicates that TDOC is somewhat dependend on debt financing.
TDOC has a worse Debt to Equity ratio (0.71) than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 7.09 | ||
| Altman-Z | -6.48 |
ROIC/WACCN/A
WACC7.76%
2.3 Liquidity
A Current Ratio of 2.70 indicates that TDOC has no problem at all paying its short term obligations.
The Current ratio of TDOC (2.70) is comparable to the rest of the industry.
TDOC has a Quick Ratio of 2.60. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.60, TDOC is in line with its industry, outperforming 54.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
TDOC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.27%.
Looking at the last year, TDOC shows a decrease in Revenue. The Revenue has decreased by -2.37% in the last year.
TDOC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.95% yearly.
EPS 1Y (TTM)-13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.37%
Revenue 1Y (TTM)-2.37%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.2%
3.2 Future
The Earnings Per Share is expected to grow by 6.70% on average over the next years.
The Revenue is expected to grow by 1.86% on average over the next years.
EPS Next Y4.23%
EPS Next 2Y17.66%
EPS Next 3Y12.29%
EPS Next 5Y6.7%
Revenue Next Year-1.79%
Revenue Next 2Y-0.31%
Revenue Next 3Y0.41%
Revenue Next 5Y1.86%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TDOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TDOC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
91.43% of the companies in the same industry are more expensive than TDOC, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, TDOC is valued cheaper than 97.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.54 | ||
| EV/EBITDA | 8.87 |
4.3 Compensation for Growth
TDOC's earnings are expected to grow with 12.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.66%
EPS Next 3Y12.29%
5. Dividend
5.1 Amount
TDOC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:TDOC (11/10/2025, 9:57:02 AM)
7.57
+0.04 (+0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners75.05%
Inst Owner Change1.36%
Ins Owners0.62%
Ins Owner Change6.12%
Market Cap1.34B
Revenue(TTM)2.53B
Net Income(TTM)-223.59M
Analysts68.13
Price Target9.33 (23.25%)
Short Float %14.27%
Short Ratio3.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.74%
Min EPS beat(2)-3.18%
Max EPS beat(2)28.67%
EPS beat(4)1
Avg EPS beat(4)-10.77%
Min EPS beat(4)-54.19%
Max EPS beat(4)28.67%
EPS beat(8)4
Avg EPS beat(8)3.56%
EPS beat(12)7
Avg EPS beat(12)-763.36%
EPS beat(16)10
Avg EPS beat(16)-740.69%
Revenue beat(2)0
Avg Revenue beat(2)-1.19%
Min Revenue beat(2)-1.88%
Max Revenue beat(2)-0.51%
Revenue beat(4)0
Avg Revenue beat(4)-1.14%
Min Revenue beat(4)-1.88%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.53%
Revenue beat(12)0
Avg Revenue beat(12)-1.49%
Revenue beat(16)0
Avg Revenue beat(16)-1.45%
PT rev (1m)1.39%
PT rev (3m)1.39%
EPS NQ rev (1m)-5.43%
EPS NQ rev (3m)-2.85%
EPS NY rev (1m)-3.91%
EPS NY rev (3m)-3.8%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-0.05%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.53 | ||
| P/FCF | 9.54 | ||
| P/OCF | 4.57 | ||
| P/B | 0.96 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.87 |
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)0.79
FCFY10.48%
OCF(TTM)1.66
OCFY21.87%
SpS14.31
BVpS7.88
TBVpS-1.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -16.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.8% | ||
| FCFM | 5.54% |
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
F-Score5
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 7.09 | ||
| Debt/EBITDA | 5.52 | ||
| Cap/Depr | 42.47% | ||
| Cap/Sales | 6.03% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 162.35% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z | -6.48 |
F-Score5
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)48.66%
Cap/Depr(5y)42.76%
Cap/Sales(3y)6.01%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.37%
EPS Next Y4.23%
EPS Next 2Y17.66%
EPS Next 3Y12.29%
EPS Next 5Y6.7%
Revenue 1Y (TTM)-2.37%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.2%
Revenue Next Year-1.79%
Revenue Next 2Y-0.31%
Revenue Next 3Y0.41%
Revenue Next 5Y1.86%
EBIT growth 1Y9.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year141.27%
EBIT Next 3Y35.38%
EBIT Next 5Y20.45%
FCF growth 1Y25.37%
FCF growth 3Y9.25%
FCF growth 5Y54.93%
OCF growth 1Y2.46%
OCF growth 3Y14.82%
OCF growth 5Y57.92%
TELADOC HEALTH INC / TDOC FAQ
What is the ChartMill fundamental rating of TELADOC HEALTH INC (TDOC) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TDOC.
What is the valuation status of TELADOC HEALTH INC (TDOC) stock?
ChartMill assigns a valuation rating of 3 / 10 to TELADOC HEALTH INC (TDOC). This can be considered as Overvalued.
Can you provide the profitability details for TELADOC HEALTH INC?
TELADOC HEALTH INC (TDOC) has a profitability rating of 3 / 10.
What is the expected EPS growth for TELADOC HEALTH INC (TDOC) stock?
The Earnings per Share (EPS) of TELADOC HEALTH INC (TDOC) is expected to grow by 4.23% in the next year.